Hypothalamic growth hormone releasing factor deficiency following cranial irradiation.
The effect of synthetic human pancreatic tumour GH releasing factor (hp GRF1-44) on GH release has been studied in 10 patients with radiation-induced GH deficiency and four normal subjects. All 10 patients showed subnormal GH responses to both an ITT (median peak GH 3.2 mU/l) and to arginine stimulation (median peak GH 2.9 mU/l), although the remainder of pituitary function was intact. Following an acute intravenous bolus (100 micrograms) of hp GRF1-44, there was no GH response in two patients and a subnormal but definite GH response in a further four. The remaining four patients showed a significant GH response (median peak GH level 29 mU/l; range 22-57 mU/l) to hp GRF1-44, similar in magnitude and timing to that seen in the four normals. This strongly suggests that in these four subjects, the discrepancy in GH responses to hp GRF1-44, ITT and to arginine was a result of radiation-induced hypothalamic damage leading to a deficiency of endogenous GRF. The availability of synthetic hp GRF capable of stimulating GH secretion means that the distinction between hypothalamic and pituitary causes of GH deficiency will be of considerable therapeutic importance in the future.
D000293:Adolescent; D000328:Adult; D001120:Arginine; D001932:Brain Neoplasms / Q000532:radiotherapy*; D002648:Child; D013006:Growth Hormone / Q000097:blood / Q000172:deficiency / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000172:deficiency*; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000528:radiation effects; D007328:Insulin; D008297:Male; D010187:Pancreatic Hormones; D010446:Peptide Fragments; D011878:Radiotherapy / Q000009:adverse effects*
D007328:Insulin; D010187:Pancreatic Hormones; D010446:Peptide Fragments; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine